HBOT Shows Promise for Postoperative Macular Edema Recovery, But FDA Approval Remains Elusive

Cross-sectional view of the human retina showing macular layers with oxygen diffusion patterns, representing postoperative macular edema treatment

When cataract surgery goes according to plan, patients expect clearer vision within days. But for a subset of individuals, the postoperative period brings an unwelcome complication: cystoid macular edema (CME), a swelling of the central retina that can blur or distort central vision for weeks or months. A newly published 2026 case report from Hungary suggests that hyperbaric oxygen therapy (HBOT) may accelerate recovery in these challenging cases—though the treatment remains outside the boundaries of FDA-approved indications for ophthalmologic conditions.

The Case: From Blurred Vision to Measurable Improvement

The study, published in Orvosi Hetilap (Hungarian Medical Journal) and indexed in PubMed (PMID: 42437467), documents the case of a patient who developed significant macular edema following intraocular surgery. Rather than waiting for spontaneous resolution—which can take months and sometimes leaves residual visual deficits—the patient underwent a course of HBOT.

The results, as captured by optical coherence tomography (OCT), were striking. The authors report that “regression of blurred vision due to postoperative macular edema accelerated significantly, with results objectified by OCT examination that cannot be explained by spontaneous improvement.” Final OCT performed one month after HBOT completion showed visual acuity of 1.0 (20/20) and macular thickness of 267 μm—within normal range.

What makes this case particularly noteworthy is the objective documentation. OCT provides cross-sectional imaging of retinal layers with micron-level precision, offering quantifiable evidence of structural improvement rather than relying solely on subjective patient reports.

Understanding Postoperative Macular Edema

Cystoid macular edema represents one of the most common causes of visual acuity reduction following intraocular surgery, particularly cataract extraction. According to a 2025 systematic review published in Diagnostics, CME presents management challenges due to the lack of standardized treatment guidelines and the potential for spontaneous resolution—leaving clinicians to weigh intervention against watchful waiting.

The condition arises when inflammation disrupts the blood-retinal barrier, causing fluid accumulation in the macula’s honeycomb-like structure. Risk factors include diabetes, uveitis, epiretinal membrane, and certain intraoperative complications. While first-line treatments typically involve topical or intravitreal anti-inflammatory medications, refractory cases pose a clinical dilemma.

The Rationale for HBOT in Retinal Conditions

Hyperbaric oxygen therapy delivers 100% oxygen at pressures exceeding atmospheric levels, typically 2.0 to 2.5 atmospheres absolute (ATA) in clinical settings. This creates a steep oxygen gradient that drives dissolved oxygen into plasma, improving tissue oxygenation even in areas with compromised circulation.

In ophthalmology, the theoretical basis for HBOT rests on several mechanisms. The retina has one of the highest metabolic demands of any tissue, with photoreceptors requiring substantial oxygen for visual transduction. When edema compromises oxygen diffusion from choroidal circulation, cellular dysfunction follows. HBOT may counteract this by:

Increasing oxygen diffusion distance into swollen retinal tissue
Reducing hypoxia-induced inflammation and vascular permeability
Promoting cellular metabolism and energy production in stressed photoreceptors
Potentially accelerating restoration of the blood-retinal barrier

A 2023 narrative review published in the Journal of Clinical Medicine surveyed HBOT applications in ophthalmology, noting its use for retinal artery occlusion, retinal vein occlusion, diabetic macular edema, and acute optic neuropathy. The review characterized these applications as showing “promising effects” while acknowledging that rigorous randomized controlled trials remain limited.

The FDA Position: What Regulators Actually Approve

Despite accumulating case reports and small studies, the U.S. Food and Drug Administration maintains a clear stance on HBOT for ophthalmologic conditions: it is not approved. The FDA’s consumer guidance explicitly states that while HBOT devices are cleared for specific medical uses—including decompression sickness, carbon monoxide poisoning, certain non-healing wounds, and late radiation tissue injury—ophthalmologic applications fall outside these indications.

This regulatory boundary matters for several reasons. Insurance coverage typically follows FDA clearance, meaning patients seeking HBOT for macular edema or other eye conditions generally face out-of-pocket costs. More critically, the absence of large-scale randomized trials means that efficacy, optimal dosing protocols, and patient selection criteria remain incompletely defined.

The FDA’s August 2025 safety letter to healthcare providers adds another layer of caution, emphasizing fire risks and device safety concerns associated with HBOT chambers. While this communication focused primarily on physical safety rather than clinical indications, it underscores the agency’s ongoing scrutiny of hyperbaric therapy practices.

Evidence Quality: Case Reports Versus Controlled Trials

The 2026 Hungarian case contributes to a growing literature of observational reports suggesting HBOT’s potential in vision-threatening conditions. However, the hierarchy of medical evidence places single-case reports near the base. Without control groups, randomization, and blinding, it remains impossible to distinguish true treatment effects from spontaneous recovery or placebo responses.

This evidentiary gap is particularly relevant for postoperative macular edema, which has a known natural history of gradual improvement. The authors of the Hungarian study acknowledge this limitation implicitly by emphasizing that their OCT-documented improvements “cannot be explained by spontaneous improvement”—an assertion that, while supported by the temporal relationship between HBOT and recovery, would require controlled trials to definitively establish.

Cochrane systematic reviews of HBOT for various conditions consistently highlight this pattern: promising observational data, limited high-quality randomized evidence, and calls for further research. The ophthalmology field is no exception.

Clinical Implications and Patient Considerations

For patients experiencing persistent postoperative macular edema, the treatment landscape offers limited options beyond standard anti-inflammatory therapy. HBOT represents a potential adjunct—or alternative for refractory cases—but one that comes with practical and financial considerations.

A typical course of HBOT involves 20 to 40 sessions, each lasting 60 to 90 minutes, delivered over several weeks. Costs vary widely but often range from $200 to $400 per session in the United States when paid out-of-pocket. For ophthalmologic indications, insurance coverage is rare, creating access barriers for many patients.

Safety considerations, while generally favorable, are not negligible. Barotrauma to ears or sinuses, temporary vision changes, and oxygen toxicity seizures represent known risks, though serious adverse events are uncommon with appropriate screening and protocols. The FDA’s 2025 safety communication specifically highlighted fire risks, noting that improper chamber operation has resulted in injuries and deaths.

The Research Horizon

The Hungarian case report joins a small but growing body of literature exploring HBOT in ophthalmology. Future research directions might include:

Randomized controlled trials comparing HBOT to standard care or sham therapy for specific ophthalmologic conditions
Dose-optimization studies to identify the most effective pressure and session protocols
Biomarker research to identify patients most likely to respond to HBOT
Long-term outcome studies tracking visual function stability after HBOT completion

Until such evidence emerges, HBOT for macular edema and other eye conditions remains an off-label application—one that individual clinicians may choose to pursue based on clinical judgment, patient preferences, and the limitations of standard therapeutic options.

Conclusion

The 2026 case report of accelerated recovery from postoperative macular edema with HBOT adds another data point to the expanding conversation about hyperbaric therapy in ophthalmology. The objective OCT documentation and temporal relationship between treatment and improvement are encouraging, particularly for a condition that can significantly impact quality of life when it persists.

Yet the gap between promising case reports and regulatory approval remains substantial. The FDA’s position is clear: HBOT is not approved for ophthalmologic indications, and patients pursuing such treatment do so outside the framework of established medical consensus. For clinicians and patients navigating refractory macular edema, this creates a familiar tension between the desire for effective interventions and the evidentiary standards that protect patient safety and ensure resource stewardship.

As research continues, the ophthalmology community awaits the randomized trials that could either validate HBOT’s role in retinal care or clarify its limitations. Until then, cases like the one reported in Hungary offer hope while underscoring the need for rigorous science to separate genuine therapeutic effects from the natural history of recovery.

Sources

← Back to blog